Description

MONOTRATE SR 60 MG

Indications

MONOTRATE SR 60 MG is primarily indicated for the management of angina pectoris, a condition characterized by chest pain due to insufficient blood flow to the heart muscle. It is also utilized in the treatment of other cardiovascular conditions where vasodilation is beneficial. The sustained-release formulation allows for prolonged therapeutic effects, making it suitable for patients requiring consistent management of their symptoms throughout the day.

Mechanism of Action

MONOTRATE SR contains isosorbide mononitrate, a nitrate that works by relaxing the smooth muscles of blood vessels. This vasodilation reduces the workload on the heart by decreasing both preload and afterload, which in turn lowers myocardial oxygen demand. By improving blood flow to the heart muscle, MONOTRATE SR alleviates the symptoms of angina and enhances exercise tolerance in patients with coronary artery disease.

Pharmacological Properties

Isosorbide mononitrate is a long-acting nitrate with a pharmacokinetic profile characterized by a slow onset of action and prolonged duration. After oral administration, the peak plasma concentration is typically reached within 1 to 2 hours, with sustained effects lasting up to 12 hours. The drug undergoes hepatic metabolism, and its bioavailability can be affected by first-pass metabolism. MONOTRATE SR is designed to release the active ingredient gradually, ensuring a steady therapeutic effect over an extended period.

Contraindications

MONOTRATE SR should not be used in patients with a known hypersensitivity to isosorbide mononitrate or any of its components. It is contraindicated in individuals with severe anemia, hypotension, or those who have experienced a recent myocardial infarction. Additionally, concurrent use with phosphodiesterase-5 inhibitors (such as sildenafil) is contraindicated due to the risk of severe hypotension.

Side Effects

Common side effects associated with MONOTRATE SR include headache, dizziness, and flushing, which are often attributed to the vasodilatory effects of the medication. Other potential side effects may include hypotension, tachycardia, and palpitations. In rare cases, patients may experience more severe reactions such as syncope or allergic reactions. It is essential for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of MONOTRATE SR for adults is typically 30 mg once daily, which may be adjusted based on individual patient response and tolerance. The maximum recommended dose is 120 mg per day. It is crucial to take the medication as prescribed, preferably in the morning, with or without food. Patients should not crush or chew the tablets, as this may alter the release mechanism and lead to increased side effects.

Interactions

MONOTRATE SR may interact with various medications, potentially leading to enhanced effects or adverse reactions. Concomitant use with other antihypertensive agents, including diuretics and beta-blockers, may result in additive hypotensive effects. Care should be taken when administering MONOTRATE SR with alcohol, as it can exacerbate the hypotensive effects. Additionally, the use of phosphodiesterase-5 inhibitors should be avoided due to the risk of severe hypotension.

Precautions

Before initiating treatment with MONOTRATE SR, healthcare providers should conduct a thorough assessment of the patient’s medical history, particularly regarding cardiovascular conditions, renal or hepatic impairment, and concurrent medications. Patients should be monitored for signs of hypotension, especially during the initial stages of treatment or after dose adjustments. Caution is advised in elderly patients, as they may be more susceptible to the side effects of nitrates.

Clinical Studies

Clinical studies have demonstrated the efficacy of MONOTRATE SR in reducing the frequency and severity of angina episodes. In a randomized, double-blind, placebo-controlled trial, patients receiving MONOTRATE SR reported a significant improvement in exercise tolerance and a reduction in angina frequency compared to those receiving placebo. Long-term studies have also indicated that MONOTRATE SR can improve quality of life and functional capacity in patients with stable angina.

Conclusion

MONOTRATE SR 60 MG is an effective therapeutic option for the management of angina pectoris and other cardiovascular conditions requiring vasodilation. Its sustained-release formulation provides prolonged relief from symptoms, making it a valuable addition to the treatment regimen for patients with coronary artery disease. As with any medication, it is essential for patients to adhere to prescribed dosages and report any adverse effects to their healthcare provider.